nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—Doxorubicin—bone cancer	0.222	1	CrCtD
Epirubicin—Anthracyclines—Doxorubicin—bone cancer	0.18	0.657	CiPCiCtD
Epirubicin—Topoisomerase Inhibitors—Doxorubicin—bone cancer	0.0942	0.343	CiPCiCtD
Epirubicin—thyroid cancer—bone cancer	0.0504	0.275	CtDrD
Epirubicin—Daunorubicin—Doxorubicin—bone cancer	0.0472	0.333	CrCrCtD
Epirubicin—Valrubicin—Doxorubicin—bone cancer	0.0472	0.333	CrCrCtD
Epirubicin—Idarubicin—Doxorubicin—bone cancer	0.0472	0.333	CrCrCtD
Epirubicin—breast cancer—bone cancer	0.041	0.224	CtDrD
Epirubicin—prostate cancer—bone cancer	0.038	0.208	CtDrD
Epirubicin—DHCR7—Doxorubicin—bone cancer	0.0362	0.292	CbGbCtD
Epirubicin—YWHAG—Doxorubicin—bone cancer	0.0362	0.292	CbGbCtD
Epirubicin—AURKA—Doxorubicin—bone cancer	0.0362	0.292	CbGbCtD
Epirubicin—peripheral nervous system neoplasm—bone cancer	0.0273	0.149	CtDrD
Epirubicin—sarcoma—bone cancer	0.0263	0.144	CtDrD
Epirubicin—TOP2A—Doxorubicin—bone cancer	0.00735	0.0593	CbGbCtD
Epirubicin—ABCC1—Doxorubicin—bone cancer	0.00407	0.0329	CbGbCtD
Epirubicin—ABCC1—Methotrexate—bone cancer	0.00395	0.0319	CbGbCtD
Epirubicin—YWHAG—Regulation of PLK1 Activity at G2/M Transition—TUBB4B—bone cancer	0.000195	0.0133	CbGpPWpGaD
Epirubicin—AURKA—G2/M Transition—TUBB4B—bone cancer	0.000193	0.0132	CbGpPWpGaD
Epirubicin—CHD1—Daunorubicin—Doxorubicin—bone cancer	0.000191	0.259	CbGdCrCtD
Epirubicin—CHD1—Idarubicin—Doxorubicin—bone cancer	0.000191	0.259	CbGdCrCtD
Epirubicin—AURKA—Mitotic G2-G2/M phases—TUBB4B—bone cancer	0.000191	0.013	CbGpPWpGaD
Epirubicin—UGT2B7—Estrogen metabolism—CYP3A4—bone cancer	0.000187	0.0128	CbGpPWpGaD
Epirubicin—PLA2G4A—Raltitrexed—Methotrexate—bone cancer	0.000183	0.248	CbGdCrCtD
Epirubicin—ABCC1—Irinotecan Pathway—CYP3A4—bone cancer	0.00018	0.0122	CbGpPWpGaD
Epirubicin—UGT2B7—Tamoxifen metabolism—CYP3A4—bone cancer	0.000166	0.0113	CbGpPWpGaD
Epirubicin—PLA2G4A—ADP signalling through P2Y purinoceptor 1—GNA11—bone cancer	0.000156	0.0106	CbGpPWpGaD
Epirubicin—UGT2B7—Metapathway biotransformation—CYP4V2—bone cancer	0.000154	0.0105	CbGpPWpGaD
Epirubicin—YWHAG—G2/M Transition—TUBB4B—bone cancer	0.000147	0.00997	CbGpPWpGaD
Epirubicin—YWHAG—Mitotic G2-G2/M phases—TUBB4B—bone cancer	0.000144	0.00983	CbGpPWpGaD
Epirubicin—ABCC1—Sphingosine 1-phosphate (S1P) pathway—GNA11—bone cancer	0.000143	0.00975	CbGpPWpGaD
Epirubicin—PLA2G4A—Signal amplification—GNA11—bone cancer	0.000131	0.00893	CbGpPWpGaD
Epirubicin—AURKA—Aurora A signaling—MDM2—bone cancer	0.000119	0.00811	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000111	0.00754	CbGpPWpGaD
Epirubicin—YWHAG—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00011	0.00752	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—RGS1—bone cancer	0.000107	0.00728	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—TNFRSF11A—bone cancer	0.0001	0.00683	CbGpPWpGaD
Epirubicin—YWHAG—a6b1 and a6b4 Integrin signaling—MET—bone cancer	9.04e-05	0.00615	CbGpPWpGaD
Epirubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—bone cancer	8.23e-05	0.0056	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—ZW10—bone cancer	8.11e-05	0.00552	CbGpPWpGaD
Epirubicin—AURKA—Integrin-linked kinase signaling—JUN—bone cancer	7.68e-05	0.00523	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—ATF1—bone cancer	7.59e-05	0.00517	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—ATF1—bone cancer	7.49e-05	0.0051	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—CHEK2—bone cancer	7.47e-05	0.00509	CbGpPWpGaD
Epirubicin—PLA2G4A—Endothelins—GNA11—bone cancer	7.44e-05	0.00507	CbGpPWpGaD
Epirubicin—Daunorubicin—CYP3A4—bone cancer	7.31e-05	0.552	CrCbGaD
Epirubicin—AURKA—Cell Cycle—ZW10—bone cancer	7.26e-05	0.00494	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—CHEK2—bone cancer	7.2e-05	0.0049	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—DHFR—bone cancer	7.1e-05	0.00483	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—ATF1—bone cancer	7.08e-05	0.00482	CbGpPWpGaD
Epirubicin—AURKA—Aurora A signaling—TP53—bone cancer	6.83e-05	0.00465	CbGpPWpGaD
Epirubicin—AURKA—Daunorubicin—Doxorubicin—bone cancer	6.28e-05	0.085	CbGdCrCtD
Epirubicin—AURKA—Idarubicin—Doxorubicin—bone cancer	6.28e-05	0.085	CbGdCrCtD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	6.24e-05	0.00425	CbGpPWpGaD
Epirubicin—ABCC1—S1P1 pathway—PTGS2—bone cancer	6.23e-05	0.00424	CbGpPWpGaD
Epirubicin—YWHAG—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	6.17e-05	0.0042	CbGpPWpGaD
Epirubicin—YWHAG—Activation of BH3-only proteins—TP53—bone cancer	6.15e-05	0.00419	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—ZW10—bone cancer	6.15e-05	0.00419	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—TUBB4B—bone cancer	6.15e-05	0.00419	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—BRCA2—bone cancer	6.1e-05	0.00415	CbGpPWpGaD
Epirubicin—Doxorubicin—CYP3A4—bone cancer	5.93e-05	0.448	CrCbGaD
Epirubicin—YWHAG—mTOR signaling pathway—BRAF—bone cancer	5.89e-05	0.00401	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—RFC1—bone cancer	5.58e-05	0.0038	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—ATF1—bone cancer	5.56e-05	0.00378	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—ZW10—bone cancer	5.5e-05	0.00374	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—TUBB4B—bone cancer	5.5e-05	0.00374	CbGpPWpGaD
Epirubicin—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	5.41e-05	0.00368	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—NDUFA12—bone cancer	5.35e-05	0.00364	CbGpPWpGaD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—DHFR—bone cancer	5e-05	0.0034	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—RFC1—bone cancer	4.99e-05	0.00339	CbGpPWpGaD
Epirubicin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	4.91e-05	0.00335	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—bone cancer	4.78e-05	0.00326	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—bone cancer	4.76e-05	0.00324	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—CDK4—bone cancer	4.7e-05	0.0032	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—TUBB4B—bone cancer	4.66e-05	0.00317	CbGpPWpGaD
Epirubicin—YWHAG—a6b1 and a6b4 Integrin signaling—EGFR—bone cancer	4.58e-05	0.00312	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	4.55e-05	0.0031	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—CDK4—bone cancer	4.53e-05	0.00308	CbGpPWpGaD
Epirubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—MDM2—bone cancer	4.52e-05	0.00308	CbGpPWpGaD
Epirubicin—UGT2B7—Phase II conjugation—GSTP1—bone cancer	4.5e-05	0.00307	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—NT5C3A—bone cancer	4.43e-05	0.00302	CbGpPWpGaD
Epirubicin—YWHAG—Intrinsic Pathway for Apoptosis—TP53—bone cancer	4.4e-05	0.003	CbGpPWpGaD
Epirubicin—TOP2A—Gastric Cancer Network 2—EGFR—bone cancer	4.31e-05	0.00294	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	4.31e-05	0.00294	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—ZW10—bone cancer	4.3e-05	0.00293	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—RFC1—bone cancer	4.23e-05	0.00288	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TUBB4B—bone cancer	4.17e-05	0.00284	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—RB1—bone cancer	4.08e-05	0.00278	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—BRAF—bone cancer	4.06e-05	0.00276	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—BRAF—bone cancer	4.01e-05	0.00273	CbGpPWpGaD
Epirubicin—YWHAG—LKB1 signaling events—TP53—bone cancer	3.99e-05	0.00271	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGF Pathway—JUN—bone cancer	3.96e-05	0.00269	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	3.94e-05	0.00268	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—RB1—bone cancer	3.94e-05	0.00268	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	3.87e-05	0.00263	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—ZW10—bone cancer	3.85e-05	0.00262	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—BRAF—bone cancer	3.79e-05	0.00258	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—RFC1—bone cancer	3.78e-05	0.00257	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—bone cancer	3.73e-05	0.00254	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—bone cancer	3.67e-05	0.0025	CbGpPWpGaD
Epirubicin—TOP2A—Gastric Cancer Network 2—TP53—bone cancer	3.62e-05	0.00247	CbGpPWpGaD
Epirubicin—PLA2G4A—Arachidonic acid metabolism—PTGS2—bone cancer	3.6e-05	0.00245	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—bone cancer	3.58e-05	0.00243	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—BRAF—bone cancer	3.53e-05	0.0024	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	3.52e-05	0.0024	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—MDM2—bone cancer	3.48e-05	0.00237	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—DHFR—bone cancer	3.46e-05	0.00235	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—GNA11—bone cancer	3.4e-05	0.00231	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—EZH2—bone cancer	3.38e-05	0.0023	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—MMP2—bone cancer	3.36e-05	0.00229	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—MDM2—bone cancer	3.36e-05	0.00228	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	3.35e-05	0.00228	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—TUBB4B—bone cancer	3.26e-05	0.00222	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—RB1—bone cancer	3.24e-05	0.00221	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	3.21e-05	0.00218	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	3.16e-05	0.00215	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—DHFR—bone cancer	3.09e-05	0.0021	CbGpPWpGaD
Epirubicin—UGT2B7—Biological oxidations—CYP3A4—bone cancer	3.08e-05	0.0021	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	3.05e-05	0.00208	CbGpPWpGaD
Epirubicin—UGT2B7—Metapathway biotransformation—CYP3A4—bone cancer	3.04e-05	0.00207	CbGpPWpGaD
Epirubicin—UGT2B7—NRF2 pathway—TGFBR2—bone cancer	3e-05	0.00204	CbGpPWpGaD
Epirubicin—UGT2B7—NRF2 pathway—GSTP1—bone cancer	3e-05	0.00204	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—SPARC—bone cancer	2.98e-05	0.00203	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—JUN—bone cancer	2.96e-05	0.00201	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—RFC1—bone cancer	2.96e-05	0.00201	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—JUN—bone cancer	2.92e-05	0.00199	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—TUBB4B—bone cancer	2.91e-05	0.00198	CbGpPWpGaD
Epirubicin—ABCC1—Arachidonic acid metabolism—PTGS2—bone cancer	2.87e-05	0.00196	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	2.85e-05	0.00194	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	2.78e-05	0.00189	CbGpPWpGaD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—JUN—bone cancer	2.77e-05	0.00188	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—MDM2—bone cancer	2.76e-05	0.00188	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—JUN—bone cancer	2.76e-05	0.00188	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	2.74e-05	0.00187	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—GNA11—bone cancer	2.73e-05	0.00186	CbGpPWpGaD
Epirubicin—PLA2G4A—Endothelins—JUN—bone cancer	2.7e-05	0.00183	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	2.68e-05	0.00182	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—RFC1—bone cancer	2.64e-05	0.0018	CbGpPWpGaD
Epirubicin—UGT2B7—Biological oxidations—GSTP1—bone cancer	2.63e-05	0.00179	CbGpPWpGaD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—CDK4—bone cancer	2.62e-05	0.00179	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—DHFR—bone cancer	2.62e-05	0.00178	CbGpPWpGaD
Epirubicin—UGT2B7—Metapathway biotransformation—GSTP1—bone cancer	2.6e-05	0.00177	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—JUN—bone cancer	2.6e-05	0.00177	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—CHEK2—bone cancer	2.58e-05	0.00176	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—JUN—bone cancer	2.57e-05	0.00175	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—MMP9—bone cancer	2.53e-05	0.00172	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—IL3—bone cancer	2.47e-05	0.00168	CbGpPWpGaD
Epirubicin—TOP2A—Daunorubicin—Doxorubicin—bone cancer	2.4e-05	0.0325	CbGdCrCtD
Epirubicin—TOP2A—Idarubicin—Doxorubicin—bone cancer	2.4e-05	0.0325	CbGdCrCtD
Epirubicin—YWHAG—Cell Cycle—DHFR—bone cancer	2.34e-05	0.00159	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—EGFR—bone cancer	2.32e-05	0.00158	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	2.32e-05	0.00158	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—EGFR—bone cancer	2.29e-05	0.00156	CbGpPWpGaD
Epirubicin—TOP2A—Mitotic G1-G1/S phases—RB1—bone cancer	2.28e-05	0.00155	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—BRCA2—bone cancer	2.19e-05	0.00149	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—EGFR—bone cancer	2.17e-05	0.00148	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—JUN—bone cancer	2.16e-05	0.00147	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—JUN—bone cancer	2.15e-05	0.00147	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—BRAF—bone cancer	2.14e-05	0.00146	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—EGFR—bone cancer	2.04e-05	0.00139	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TP53—bone cancer	2e-05	0.00136	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	1.99e-05	0.00135	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—CHEK2—bone cancer	1.96e-05	0.00133	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—ENO2—bone cancer	1.94e-05	0.00132	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—TP53—bone cancer	1.93e-05	0.00131	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—CDK4—bone cancer	1.91e-05	0.0013	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—TUBB4B—bone cancer	1.85e-05	0.00126	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—NDUFA12—bone cancer	1.85e-05	0.00126	CbGpPWpGaD
Epirubicin—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—bone cancer	1.84e-05	0.00126	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—DHFR—bone cancer	1.83e-05	0.00125	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—CDK4—bone cancer	1.82e-05	0.00124	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—NDUFA12—bone cancer	1.81e-05	0.00123	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—DHFR—bone cancer	1.8e-05	0.00123	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	1.72e-05	0.00117	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—GNA11—bone cancer	1.68e-05	0.00115	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—BRCA2—bone cancer	1.66e-05	0.00113	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—DHFR—bone cancer	1.64e-05	0.00112	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—CDK4—bone cancer	1.62e-05	0.00111	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.6e-05	0.00109	CbGpPWpGaD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—bone cancer	1.59e-05	0.00108	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—RB1—bone cancer	1.58e-05	0.00107	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—JUN—bone cancer	1.56e-05	0.00106	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—SPARC—bone cancer	1.54e-05	0.00105	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—NT5C3A—bone cancer	1.53e-05	0.00104	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—CYP3A4—bone cancer	1.53e-05	0.00104	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.52e-05	0.00103	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—NT5C3A—bone cancer	1.5e-05	0.00102	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	1.47e-05	0.001	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NDUFA12—bone cancer	1.45e-05	0.000985	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—GRM4—bone cancer	1.44e-05	0.000983	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—RGS1—bone cancer	1.44e-05	0.000983	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—TP53—bone cancer	1.43e-05	0.000973	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	1.42e-05	0.000967	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—RB1—bone cancer	1.41e-05	0.000961	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—GNA11—bone cancer	1.41e-05	0.000957	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CDK4—bone cancer	1.38e-05	0.000937	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—CHEK2—bone cancer	1.37e-05	0.000932	CbGpPWpGaD
Epirubicin—Asthma—Methotrexate—bone cancer	1.36e-05	0.000348	CcSEcCtD
Epirubicin—Eosinophilia—Methotrexate—bone cancer	1.34e-05	0.000344	CcSEcCtD
Epirubicin—Anorexia—Cisplatin—bone cancer	1.34e-05	0.000343	CcSEcCtD
Epirubicin—Affect lability—Doxorubicin—bone cancer	1.34e-05	0.000343	CcSEcCtD
Epirubicin—Migraine—Doxorubicin—bone cancer	1.34e-05	0.000343	CcSEcCtD
Epirubicin—Pancreatitis—Methotrexate—bone cancer	1.33e-05	0.000341	CcSEcCtD
Epirubicin—Hypotension—Cisplatin—bone cancer	1.31e-05	0.000337	CcSEcCtD
Epirubicin—Face oedema—Doxorubicin—bone cancer	1.31e-05	0.000336	CcSEcCtD
Epirubicin—DHCR7—Metabolism—GSTP1—bone cancer	1.31e-05	0.000889	CbGpPWpGaD
Epirubicin—Cardiac arrest—Doxorubicin—bone cancer	1.29e-05	0.000331	CcSEcCtD
Epirubicin—Pancytopenia—Methotrexate—bone cancer	1.29e-05	0.00033	CcSEcCtD
Epirubicin—Mood swings—Doxorubicin—bone cancer	1.29e-05	0.00033	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.28e-05	0.000872	CbGpPWpGaD
Epirubicin—Musculoskeletal discomfort—Cisplatin—bone cancer	1.28e-05	0.000328	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	1.28e-05	0.000869	CbGpPWpGaD
Epirubicin—Ataxia—Doxorubicin—bone cancer	1.28e-05	0.000327	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—IL3—bone cancer	1.27e-05	0.000867	CbGpPWpGaD
Epirubicin—Blood creatinine increased—Doxorubicin—bone cancer	1.27e-05	0.000326	CcSEcCtD
Epirubicin—Dysuria—Methotrexate—bone cancer	1.27e-05	0.000325	CcSEcCtD
Epirubicin—Neutropenia—Methotrexate—bone cancer	1.27e-05	0.000325	CcSEcCtD
Epirubicin—Dehydration—Doxorubicin—bone cancer	1.26e-05	0.000324	CcSEcCtD
Epirubicin—Paraesthesia—Cisplatin—bone cancer	1.26e-05	0.000323	CcSEcCtD
Epirubicin—Upper respiratory tract infection—Methotrexate—bone cancer	1.26e-05	0.000323	CcSEcCtD
Epirubicin—Liver function test abnormal—Doxorubicin—bone cancer	1.25e-05	0.000322	CcSEcCtD
Epirubicin—Dyspnoea—Cisplatin—bone cancer	1.25e-05	0.000321	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—GRM1—bone cancer	1.25e-05	0.000852	CbGpPWpGaD
Epirubicin—Dry skin—Doxorubicin—bone cancer	1.24e-05	0.000319	CcSEcCtD
Epirubicin—Abdominal pain upper—Doxorubicin—bone cancer	1.24e-05	0.000318	CcSEcCtD
Epirubicin—Orthostatic hypotension—Doxorubicin—bone cancer	1.24e-05	0.000318	CcSEcCtD
Epirubicin—Photosensitivity reaction—Methotrexate—bone cancer	1.24e-05	0.000317	CcSEcCtD
Epirubicin—Hypokalaemia—Doxorubicin—bone cancer	1.24e-05	0.000317	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	1.23e-05	0.000838	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—CDK4—bone cancer	1.23e-05	0.000838	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—JUN—bone cancer	1.23e-05	0.000837	CbGpPWpGaD
Epirubicin—Breast disorder—Doxorubicin—bone cancer	1.23e-05	0.000315	CcSEcCtD
Epirubicin—Aspartate aminotransferase increased—Doxorubicin—bone cancer	1.22e-05	0.000314	CcSEcCtD
Epirubicin—Toxic epidermal necrolysis—Doxorubicin—bone cancer	1.22e-05	0.000314	CcSEcCtD
Epirubicin—Decreased appetite—Cisplatin—bone cancer	1.22e-05	0.000313	CcSEcCtD
Epirubicin—Pneumonia—Methotrexate—bone cancer	1.22e-05	0.000312	CcSEcCtD
Epirubicin—Nasopharyngitis—Doxorubicin—bone cancer	1.21e-05	0.000311	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Cisplatin—bone cancer	1.21e-05	0.000311	CcSEcCtD
Epirubicin—Infestation NOS—Methotrexate—bone cancer	1.21e-05	0.00031	CcSEcCtD
Epirubicin—Infestation—Methotrexate—bone cancer	1.21e-05	0.00031	CcSEcCtD
Epirubicin—Drowsiness—Methotrexate—bone cancer	1.21e-05	0.00031	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—MDM2—bone cancer	1.2e-05	0.000819	CbGpPWpGaD
Epirubicin—Gastritis—Doxorubicin—bone cancer	1.2e-05	0.000308	CcSEcCtD
Epirubicin—Pain—Cisplatin—bone cancer	1.2e-05	0.000308	CcSEcCtD
Epirubicin—ABCC1—Metabolism—NT5C3A—bone cancer	1.2e-05	0.000816	CbGpPWpGaD
Epirubicin—Stevens-Johnson syndrome—Methotrexate—bone cancer	1.2e-05	0.000307	CcSEcCtD
Epirubicin—Alanine aminotransferase increased—Doxorubicin—bone cancer	1.2e-05	0.000307	CcSEcCtD
Epirubicin—Muscular weakness—Doxorubicin—bone cancer	1.2e-05	0.000307	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—RB1—bone cancer	1.2e-05	0.000815	CbGpPWpGaD
Epirubicin—Renal failure—Methotrexate—bone cancer	1.19e-05	0.000305	CcSEcCtD
Epirubicin—Abdominal distension—Doxorubicin—bone cancer	1.18e-05	0.000303	CcSEcCtD
Epirubicin—Stomatitis—Methotrexate—bone cancer	1.18e-05	0.000302	CcSEcCtD
Epirubicin—Conjunctivitis—Methotrexate—bone cancer	1.17e-05	0.000301	CcSEcCtD
Epirubicin—Influenza—Doxorubicin—bone cancer	1.17e-05	0.000301	CcSEcCtD
Epirubicin—Asthma—Doxorubicin—bone cancer	1.17e-05	0.000301	CcSEcCtD
Epirubicin—Dysphagia—Doxorubicin—bone cancer	1.17e-05	0.000301	CcSEcCtD
Epirubicin—Eosinophilia—Doxorubicin—bone cancer	1.16e-05	0.000298	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—BRCA2—bone cancer	1.16e-05	0.00079	CbGpPWpGaD
Epirubicin—Sweating—Methotrexate—bone cancer	1.16e-05	0.000297	CcSEcCtD
Epirubicin—Feeling abnormal—Cisplatin—bone cancer	1.16e-05	0.000297	CcSEcCtD
Epirubicin—Haematuria—Methotrexate—bone cancer	1.15e-05	0.000295	CcSEcCtD
Epirubicin—Pancreatitis—Doxorubicin—bone cancer	1.15e-05	0.000295	CcSEcCtD
Epirubicin—Angina pectoris—Doxorubicin—bone cancer	1.14e-05	0.000293	CcSEcCtD
Epirubicin—Hepatobiliary disease—Methotrexate—bone cancer	1.14e-05	0.000293	CcSEcCtD
Epirubicin—Epistaxis—Methotrexate—bone cancer	1.14e-05	0.000292	CcSEcCtD
Epirubicin—Bronchitis—Doxorubicin—bone cancer	1.13e-05	0.000289	CcSEcCtD
Epirubicin—Agranulocytosis—Methotrexate—bone cancer	1.13e-05	0.000289	CcSEcCtD
Epirubicin—Pancytopenia—Doxorubicin—bone cancer	1.11e-05	0.000286	CcSEcCtD
Epirubicin—Body temperature increased—Cisplatin—bone cancer	1.11e-05	0.000285	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.11e-05	0.000755	CbGpPWpGaD
Epirubicin—Dysuria—Doxorubicin—bone cancer	1.1e-05	0.000281	CcSEcCtD
Epirubicin—Neutropenia—Doxorubicin—bone cancer	1.1e-05	0.000281	CcSEcCtD
Epirubicin—Upper respiratory tract infection—Doxorubicin—bone cancer	1.09e-05	0.00028	CcSEcCtD
Epirubicin—Haemoglobin—Methotrexate—bone cancer	1.09e-05	0.00028	CcSEcCtD
Epirubicin—Hepatitis—Methotrexate—bone cancer	1.08e-05	0.000278	CcSEcCtD
Epirubicin—Haemorrhage—Methotrexate—bone cancer	1.08e-05	0.000278	CcSEcCtD
Epirubicin—Pollakiuria—Doxorubicin—bone cancer	1.08e-05	0.000278	CcSEcCtD
Epirubicin—Pharyngitis—Methotrexate—bone cancer	1.08e-05	0.000276	CcSEcCtD
Epirubicin—Urinary tract disorder—Methotrexate—bone cancer	1.07e-05	0.000275	CcSEcCtD
Epirubicin—Photosensitivity reaction—Doxorubicin—bone cancer	1.07e-05	0.000275	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—RB1—bone cancer	1.07e-05	0.000728	CbGpPWpGaD
Epirubicin—Weight increased—Doxorubicin—bone cancer	1.07e-05	0.000274	CcSEcCtD
Epirubicin—Urethral disorder—Methotrexate—bone cancer	1.06e-05	0.000273	CcSEcCtD
Epirubicin—Weight decreased—Doxorubicin—bone cancer	1.06e-05	0.000272	CcSEcCtD
Epirubicin—Hyperglycaemia—Doxorubicin—bone cancer	1.06e-05	0.000272	CcSEcCtD
Epirubicin—Pneumonia—Doxorubicin—bone cancer	1.05e-05	0.00027	CcSEcCtD
Epirubicin—Drowsiness—Doxorubicin—bone cancer	1.05e-05	0.000268	CcSEcCtD
Epirubicin—Infestation NOS—Doxorubicin—bone cancer	1.05e-05	0.000268	CcSEcCtD
Epirubicin—Infestation—Doxorubicin—bone cancer	1.05e-05	0.000268	CcSEcCtD
Epirubicin—Visual impairment—Methotrexate—bone cancer	1.05e-05	0.000268	CcSEcCtD
Epirubicin—Stevens-Johnson syndrome—Doxorubicin—bone cancer	1.04e-05	0.000266	CcSEcCtD
Epirubicin—Hypersensitivity—Cisplatin—bone cancer	1.03e-05	0.000265	CcSEcCtD
Epirubicin—Renal failure—Doxorubicin—bone cancer	1.03e-05	0.000264	CcSEcCtD
Epirubicin—Erythema multiforme—Methotrexate—bone cancer	1.03e-05	0.000263	CcSEcCtD
Epirubicin—Neuropathy peripheral—Doxorubicin—bone cancer	1.03e-05	0.000263	CcSEcCtD
Epirubicin—Stomatitis—Doxorubicin—bone cancer	1.02e-05	0.000262	CcSEcCtD
Epirubicin—Jaundice—Doxorubicin—bone cancer	1.02e-05	0.000262	CcSEcCtD
Epirubicin—Conjunctivitis—Doxorubicin—bone cancer	1.02e-05	0.000261	CcSEcCtD
Epirubicin—Urinary tract infection—Doxorubicin—bone cancer	1.02e-05	0.000261	CcSEcCtD
Epirubicin—Eye disorder—Methotrexate—bone cancer	1.01e-05	0.00026	CcSEcCtD
Epirubicin—Tinnitus—Methotrexate—bone cancer	1.01e-05	0.000259	CcSEcCtD
Epirubicin—Asthenia—Cisplatin—bone cancer	1.01e-05	0.000258	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	1.01e-05	0.000686	CbGpPWpGaD
Epirubicin—Cardiac disorder—Methotrexate—bone cancer	1.01e-05	0.000258	CcSEcCtD
Epirubicin—Sweating—Doxorubicin—bone cancer	1e-05	0.000257	CcSEcCtD
Epirubicin—Haematuria—Doxorubicin—bone cancer	9.98e-06	0.000256	CcSEcCtD
Epirubicin—Hepatobiliary disease—Doxorubicin—bone cancer	9.89e-06	0.000254	CcSEcCtD
Epirubicin—Epistaxis—Doxorubicin—bone cancer	9.87e-06	0.000253	CcSEcCtD
Epirubicin—Angiopathy—Methotrexate—bone cancer	9.84e-06	0.000252	CcSEcCtD
Epirubicin—Sinusitis—Doxorubicin—bone cancer	9.82e-06	0.000252	CcSEcCtD
Epirubicin—Immune system disorder—Methotrexate—bone cancer	9.8e-06	0.000251	CcSEcCtD
Epirubicin—Mediastinal disorder—Methotrexate—bone cancer	9.78e-06	0.000251	CcSEcCtD
Epirubicin—Agranulocytosis—Doxorubicin—bone cancer	9.76e-06	0.00025	CcSEcCtD
Epirubicin—Chills—Methotrexate—bone cancer	9.73e-06	0.00025	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CDK4—bone cancer	9.62e-06	0.000655	CbGpPWpGaD
Epirubicin—Diarrhoea—Cisplatin—bone cancer	9.61e-06	0.000246	CcSEcCtD
Epirubicin—Alopecia—Methotrexate—bone cancer	9.58e-06	0.000246	CcSEcCtD
Epirubicin—Bradycardia—Doxorubicin—bone cancer	9.56e-06	0.000245	CcSEcCtD
Epirubicin—Mental disorder—Methotrexate—bone cancer	9.5e-06	0.000244	CcSEcCtD
Epirubicin—Malnutrition—Methotrexate—bone cancer	9.44e-06	0.000242	CcSEcCtD
Epirubicin—Erythema—Methotrexate—bone cancer	9.44e-06	0.000242	CcSEcCtD
Epirubicin—Haemoglobin—Doxorubicin—bone cancer	9.44e-06	0.000242	CcSEcCtD
Epirubicin—Rhinitis—Doxorubicin—bone cancer	9.42e-06	0.000242	CcSEcCtD
Epirubicin—Haemorrhage—Doxorubicin—bone cancer	9.39e-06	0.000241	CcSEcCtD
Epirubicin—Hepatitis—Doxorubicin—bone cancer	9.39e-06	0.000241	CcSEcCtD
Epirubicin—Hypoaesthesia—Doxorubicin—bone cancer	9.35e-06	0.00024	CcSEcCtD
Epirubicin—Pharyngitis—Doxorubicin—bone cancer	9.32e-06	0.000239	CcSEcCtD
Epirubicin—Urinary tract disorder—Doxorubicin—bone cancer	9.28e-06	0.000238	CcSEcCtD
Epirubicin—Oedema peripheral—Doxorubicin—bone cancer	9.25e-06	0.000237	CcSEcCtD
Epirubicin—Dysgeusia—Methotrexate—bone cancer	9.25e-06	0.000237	CcSEcCtD
Epirubicin—Connective tissue disorder—Doxorubicin—bone cancer	9.23e-06	0.000237	CcSEcCtD
Epirubicin—Urethral disorder—Doxorubicin—bone cancer	9.21e-06	0.000236	CcSEcCtD
Epirubicin—Back pain—Methotrexate—bone cancer	9.13e-06	0.000234	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—MDM2—bone cancer	9.12e-06	0.000621	CbGpPWpGaD
Epirubicin—Visual impairment—Doxorubicin—bone cancer	9.05e-06	0.000232	CcSEcCtD
Epirubicin—Vomiting—Cisplatin—bone cancer	8.93e-06	0.000229	CcSEcCtD
Epirubicin—Vision blurred—Methotrexate—bone cancer	8.9e-06	0.000228	CcSEcCtD
Epirubicin—Erythema multiforme—Doxorubicin—bone cancer	8.88e-06	0.000228	CcSEcCtD
Epirubicin—Rash—Cisplatin—bone cancer	8.85e-06	0.000227	CcSEcCtD
Epirubicin—Dermatitis—Cisplatin—bone cancer	8.85e-06	0.000227	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—SMO—bone cancer	8.82e-06	0.0006	CbGpPWpGaD
Epirubicin—Eye disorder—Doxorubicin—bone cancer	8.78e-06	0.000225	CcSEcCtD
Epirubicin—Ill-defined disorder—Methotrexate—bone cancer	8.76e-06	0.000225	CcSEcCtD
Epirubicin—Tinnitus—Doxorubicin—bone cancer	8.76e-06	0.000225	CcSEcCtD
Epirubicin—Anaemia—Methotrexate—bone cancer	8.73e-06	0.000224	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	8.73e-06	0.000594	CbGpPWpGaD
Epirubicin—Cardiac disorder—Doxorubicin—bone cancer	8.72e-06	0.000224	CcSEcCtD
Epirubicin—Flushing—Doxorubicin—bone cancer	8.72e-06	0.000224	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—CDK4—bone cancer	8.61e-06	0.000586	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—RGS1—bone cancer	8.53e-06	0.000581	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—GRM4—bone cancer	8.53e-06	0.000581	CbGpPWpGaD
Epirubicin—Angiopathy—Doxorubicin—bone cancer	8.52e-06	0.000219	CcSEcCtD
Epirubicin—Malaise—Methotrexate—bone cancer	8.51e-06	0.000218	CcSEcCtD
Epirubicin—Immune system disorder—Doxorubicin—bone cancer	8.48e-06	0.000218	CcSEcCtD
Epirubicin—Vertigo—Methotrexate—bone cancer	8.48e-06	0.000218	CcSEcCtD
Epirubicin—Mediastinal disorder—Doxorubicin—bone cancer	8.46e-06	0.000217	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	8.46e-06	0.000576	CbGpPWpGaD
Epirubicin—Leukopenia—Methotrexate—bone cancer	8.45e-06	0.000217	CcSEcCtD
Epirubicin—Chills—Doxorubicin—bone cancer	8.43e-06	0.000216	CcSEcCtD
Epirubicin—Arrhythmia—Doxorubicin—bone cancer	8.39e-06	0.000215	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—RB1—bone cancer	8.37e-06	0.00057	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—PLAU—bone cancer	8.36e-06	0.000569	CbGpPWpGaD
Epirubicin—Nausea—Cisplatin—bone cancer	8.34e-06	0.000214	CcSEcCtD
Epirubicin—Alopecia—Doxorubicin—bone cancer	8.3e-06	0.000213	CcSEcCtD
Epirubicin—Cough—Methotrexate—bone cancer	8.24e-06	0.000211	CcSEcCtD
Epirubicin—Mental disorder—Doxorubicin—bone cancer	8.23e-06	0.000211	CcSEcCtD
Epirubicin—Convulsion—Methotrexate—bone cancer	8.18e-06	0.00021	CcSEcCtD
Epirubicin—Erythema—Doxorubicin—bone cancer	8.18e-06	0.00021	CcSEcCtD
Epirubicin—Malnutrition—Doxorubicin—bone cancer	8.18e-06	0.00021	CcSEcCtD
Epirubicin—TOP2A—Circadian rythm related genes—TP53—bone cancer	8.12e-06	0.000553	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—GNA11—bone cancer	8.07e-06	0.000549	CbGpPWpGaD
Epirubicin—Flatulence—Doxorubicin—bone cancer	8.06e-06	0.000207	CcSEcCtD
Epirubicin—Arthralgia—Methotrexate—bone cancer	8.04e-06	0.000206	CcSEcCtD
Epirubicin—Myalgia—Methotrexate—bone cancer	8.04e-06	0.000206	CcSEcCtD
Epirubicin—Chest pain—Methotrexate—bone cancer	8.04e-06	0.000206	CcSEcCtD
Epirubicin—Tension—Doxorubicin—bone cancer	8.02e-06	0.000206	CcSEcCtD
Epirubicin—Dysgeusia—Doxorubicin—bone cancer	8.01e-06	0.000205	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	7.98e-06	0.000205	CcSEcCtD
Epirubicin—Discomfort—Methotrexate—bone cancer	7.94e-06	0.000204	CcSEcCtD
Epirubicin—Nervousness—Doxorubicin—bone cancer	7.94e-06	0.000204	CcSEcCtD
Epirubicin—Back pain—Doxorubicin—bone cancer	7.91e-06	0.000203	CcSEcCtD
Epirubicin—Muscle spasms—Doxorubicin—bone cancer	7.86e-06	0.000202	CcSEcCtD
Epirubicin—Confusional state—Methotrexate—bone cancer	7.77e-06	0.000199	CcSEcCtD
Epirubicin—Anaphylactic shock—Methotrexate—bone cancer	7.71e-06	0.000198	CcSEcCtD
Epirubicin—Vision blurred—Doxorubicin—bone cancer	7.71e-06	0.000198	CcSEcCtD
Epirubicin—Infection—Methotrexate—bone cancer	7.66e-06	0.000196	CcSEcCtD
Epirubicin—Ill-defined disorder—Doxorubicin—bone cancer	7.59e-06	0.000195	CcSEcCtD
Epirubicin—Nervous system disorder—Methotrexate—bone cancer	7.56e-06	0.000194	CcSEcCtD
Epirubicin—Anaemia—Doxorubicin—bone cancer	7.56e-06	0.000194	CcSEcCtD
Epirubicin—Thrombocytopenia—Methotrexate—bone cancer	7.55e-06	0.000194	CcSEcCtD
Epirubicin—Agitation—Doxorubicin—bone cancer	7.51e-06	0.000193	CcSEcCtD
Epirubicin—Skin disorder—Methotrexate—bone cancer	7.49e-06	0.000192	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—RB1—bone cancer	7.48e-06	0.000509	CbGpPWpGaD
Epirubicin—Hyperhidrosis—Methotrexate—bone cancer	7.45e-06	0.000191	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—GRM1—bone cancer	7.39e-06	0.000503	CbGpPWpGaD
Epirubicin—Malaise—Doxorubicin—bone cancer	7.37e-06	0.000189	CcSEcCtD
Epirubicin—Vertigo—Doxorubicin—bone cancer	7.35e-06	0.000188	CcSEcCtD
Epirubicin—Anorexia—Methotrexate—bone cancer	7.35e-06	0.000188	CcSEcCtD
Epirubicin—Syncope—Doxorubicin—bone cancer	7.33e-06	0.000188	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	7.33e-06	0.000499	CbGpPWpGaD
Epirubicin—Leukopenia—Doxorubicin—bone cancer	7.32e-06	0.000188	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—IL3—bone cancer	7.31e-06	0.000498	CbGpPWpGaD
Epirubicin—Palpitations—Doxorubicin—bone cancer	7.23e-06	0.000185	CcSEcCtD
Epirubicin—Hypotension—Methotrexate—bone cancer	7.2e-06	0.000185	CcSEcCtD
Epirubicin—Loss of consciousness—Doxorubicin—bone cancer	7.19e-06	0.000184	CcSEcCtD
Epirubicin—Cough—Doxorubicin—bone cancer	7.13e-06	0.000183	CcSEcCtD
Epirubicin—Convulsion—Doxorubicin—bone cancer	7.08e-06	0.000182	CcSEcCtD
Epirubicin—Hypertension—Doxorubicin—bone cancer	7.06e-06	0.000181	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Methotrexate—bone cancer	7.02e-06	0.00018	CcSEcCtD
Epirubicin—Insomnia—Methotrexate—bone cancer	6.97e-06	0.000179	CcSEcCtD
Epirubicin—Chest pain—Doxorubicin—bone cancer	6.96e-06	0.000179	CcSEcCtD
Epirubicin—Myalgia—Doxorubicin—bone cancer	6.96e-06	0.000179	CcSEcCtD
Epirubicin—Arthralgia—Doxorubicin—bone cancer	6.96e-06	0.000179	CcSEcCtD
Epirubicin—Anxiety—Doxorubicin—bone cancer	6.94e-06	0.000178	CcSEcCtD
Epirubicin—Paraesthesia—Methotrexate—bone cancer	6.92e-06	0.000177	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	6.91e-06	0.000177	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—TP53—bone cancer	6.91e-06	0.00047	CbGpPWpGaD
Epirubicin—Discomfort—Doxorubicin—bone cancer	6.88e-06	0.000176	CcSEcCtD
Epirubicin—Dyspnoea—Methotrexate—bone cancer	6.87e-06	0.000176	CcSEcCtD
Epirubicin—Somnolence—Methotrexate—bone cancer	6.85e-06	0.000176	CcSEcCtD
Epirubicin—Dry mouth—Doxorubicin—bone cancer	6.81e-06	0.000175	CcSEcCtD
Epirubicin—Dyspepsia—Methotrexate—bone cancer	6.78e-06	0.000174	CcSEcCtD
Epirubicin—DHCR7—Metabolism—PTGS2—bone cancer	6.76e-06	0.00046	CbGpPWpGaD
Epirubicin—Confusional state—Doxorubicin—bone cancer	6.73e-06	0.000173	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—ENO2—bone cancer	6.7e-06	0.000456	CbGpPWpGaD
Epirubicin—Decreased appetite—Methotrexate—bone cancer	6.7e-06	0.000172	CcSEcCtD
Epirubicin—Anaphylactic shock—Doxorubicin—bone cancer	6.67e-06	0.000171	CcSEcCtD
Epirubicin—Oedema—Doxorubicin—bone cancer	6.67e-06	0.000171	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Methotrexate—bone cancer	6.65e-06	0.000171	CcSEcCtD
Epirubicin—Fatigue—Methotrexate—bone cancer	6.64e-06	0.00017	CcSEcCtD
Epirubicin—Infection—Doxorubicin—bone cancer	6.63e-06	0.00017	CcSEcCtD
Epirubicin—Pain—Methotrexate—bone cancer	6.59e-06	0.000169	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—ENO2—bone cancer	6.57e-06	0.000447	CbGpPWpGaD
Epirubicin—Shock—Doxorubicin—bone cancer	6.56e-06	0.000168	CcSEcCtD
Epirubicin—Nervous system disorder—Doxorubicin—bone cancer	6.54e-06	0.000168	CcSEcCtD
Epirubicin—Thrombocytopenia—Doxorubicin—bone cancer	6.53e-06	0.000168	CcSEcCtD
Epirubicin—Tachycardia—Doxorubicin—bone cancer	6.51e-06	0.000167	CcSEcCtD
Epirubicin—Skin disorder—Doxorubicin—bone cancer	6.48e-06	0.000166	CcSEcCtD
Epirubicin—Hyperhidrosis—Doxorubicin—bone cancer	6.45e-06	0.000165	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—MDM2—bone cancer	6.38e-06	0.000434	CbGpPWpGaD
Epirubicin—Anorexia—Doxorubicin—bone cancer	6.36e-06	0.000163	CcSEcCtD
Epirubicin—Feeling abnormal—Methotrexate—bone cancer	6.35e-06	0.000163	CcSEcCtD
Epirubicin—Gastrointestinal pain—Methotrexate—bone cancer	6.3e-06	0.000162	CcSEcCtD
Epirubicin—ABCC1—Disease—ENO2—bone cancer	6.27e-06	0.000427	CbGpPWpGaD
Epirubicin—Hypotension—Doxorubicin—bone cancer	6.24e-06	0.00016	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—DHFR—bone cancer	6.22e-06	0.000423	CbGpPWpGaD
Epirubicin—Urticaria—Methotrexate—bone cancer	6.12e-06	0.000157	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—DHFR—bone cancer	6.1e-06	0.000415	CbGpPWpGaD
Epirubicin—Abdominal pain—Methotrexate—bone cancer	6.09e-06	0.000156	CcSEcCtD
Epirubicin—Body temperature increased—Methotrexate—bone cancer	6.09e-06	0.000156	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Doxorubicin—bone cancer	6.08e-06	0.000156	CcSEcCtD
Epirubicin—Insomnia—Doxorubicin—bone cancer	6.04e-06	0.000155	CcSEcCtD
Epirubicin—Paraesthesia—Doxorubicin—bone cancer	5.99e-06	0.000154	CcSEcCtD
Epirubicin—Dyspnoea—Doxorubicin—bone cancer	5.95e-06	0.000153	CcSEcCtD
Epirubicin—Somnolence—Doxorubicin—bone cancer	5.93e-06	0.000152	CcSEcCtD
Epirubicin—Dyspepsia—Doxorubicin—bone cancer	5.87e-06	0.000151	CcSEcCtD
Epirubicin—ABCC1—Disease—DHFR—bone cancer	5.82e-06	0.000396	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GNA11—bone cancer	5.81e-06	0.000396	CbGpPWpGaD
Epirubicin—Decreased appetite—Doxorubicin—bone cancer	5.8e-06	0.000149	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Doxorubicin—bone cancer	5.76e-06	0.000148	CcSEcCtD
Epirubicin—Fatigue—Doxorubicin—bone cancer	5.75e-06	0.000148	CcSEcCtD
Epirubicin—Constipation—Doxorubicin—bone cancer	5.71e-06	0.000146	CcSEcCtD
Epirubicin—Pain—Doxorubicin—bone cancer	5.71e-06	0.000146	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—GNA11—bone cancer	5.7e-06	0.000388	CbGpPWpGaD
Epirubicin—Hypersensitivity—Methotrexate—bone cancer	5.68e-06	0.000146	CcSEcCtD
Epirubicin—Asthenia—Methotrexate—bone cancer	5.53e-06	0.000142	CcSEcCtD
Epirubicin—Feeling abnormal—Doxorubicin—bone cancer	5.5e-06	0.000141	CcSEcCtD
Epirubicin—Gastrointestinal pain—Doxorubicin—bone cancer	5.46e-06	0.00014	CcSEcCtD
Epirubicin—Pruritus—Methotrexate—bone cancer	5.45e-06	0.00014	CcSEcCtD
Epirubicin—Urticaria—Doxorubicin—bone cancer	5.3e-06	0.000136	CcSEcCtD
Epirubicin—Abdominal pain—Doxorubicin—bone cancer	5.27e-06	0.000135	CcSEcCtD
Epirubicin—Body temperature increased—Doxorubicin—bone cancer	5.27e-06	0.000135	CcSEcCtD
Epirubicin—Diarrhoea—Methotrexate—bone cancer	5.27e-06	0.000135	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—CYP3A4—bone cancer	5.27e-06	0.000359	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ENO2—bone cancer	5.25e-06	0.000357	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TP53—bone cancer	5.23e-06	0.000356	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—SMO—bone cancer	5.21e-06	0.000355	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CYP3A4—bone cancer	5.17e-06	0.000352	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.14e-06	0.00035	CbGpPWpGaD
Epirubicin—Dizziness—Methotrexate—bone cancer	5.1e-06	0.000131	CcSEcCtD
Epirubicin—Hypersensitivity—Doxorubicin—bone cancer	4.92e-06	0.000126	CcSEcCtD
Epirubicin—Vomiting—Methotrexate—bone cancer	4.9e-06	0.000126	CcSEcCtD
Epirubicin—ABCC1—Metabolism—DHFR—bone cancer	4.87e-06	0.000332	CbGpPWpGaD
Epirubicin—Rash—Methotrexate—bone cancer	4.86e-06	0.000125	CcSEcCtD
Epirubicin—Dermatitis—Methotrexate—bone cancer	4.85e-06	0.000125	CcSEcCtD
Epirubicin—Headache—Methotrexate—bone cancer	4.83e-06	0.000124	CcSEcCtD
Epirubicin—Asthenia—Doxorubicin—bone cancer	4.79e-06	0.000123	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—GNA11—bone cancer	4.76e-06	0.000324	CbGpPWpGaD
Epirubicin—Pruritus—Doxorubicin—bone cancer	4.72e-06	0.000121	CcSEcCtD
Epirubicin—Nausea—Methotrexate—bone cancer	4.58e-06	0.000117	CcSEcCtD
Epirubicin—Diarrhoea—Doxorubicin—bone cancer	4.57e-06	0.000117	CcSEcCtD
Epirubicin—ABCC1—Metabolism—GNA11—bone cancer	4.55e-06	0.00031	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GSTP1—bone cancer	4.51e-06	0.000307	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ATF1—bone cancer	4.43e-06	0.000302	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—GSTP1—bone cancer	4.42e-06	0.000301	CbGpPWpGaD
Epirubicin—Dizziness—Doxorubicin—bone cancer	4.41e-06	0.000113	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—IL3—bone cancer	4.32e-06	0.000294	CbGpPWpGaD
Epirubicin—Vomiting—Doxorubicin—bone cancer	4.24e-06	0.000109	CcSEcCtD
Epirubicin—ABCC1—Disease—TGFBR2—bone cancer	4.22e-06	0.000287	CbGpPWpGaD
Epirubicin—Rash—Doxorubicin—bone cancer	4.21e-06	0.000108	CcSEcCtD
Epirubicin—Dermatitis—Doxorubicin—bone cancer	4.2e-06	0.000108	CcSEcCtD
Epirubicin—Headache—Doxorubicin—bone cancer	4.18e-06	0.000107	CcSEcCtD
Epirubicin—ABCC1—Metabolism—CYP3A4—bone cancer	4.13e-06	0.000281	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.11e-06	0.00028	CbGpPWpGaD
Epirubicin—Nausea—Doxorubicin—bone cancer	3.96e-06	0.000102	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—TGFBR2—bone cancer	3.69e-06	0.000251	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—TP53—bone cancer	3.66e-06	0.000249	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GSTP1—bone cancer	3.53e-06	0.00024	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—IGF1R—bone cancer	3.48e-06	0.000237	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TP53—bone cancer	3.36e-06	0.000229	CbGpPWpGaD
Epirubicin—ABCC1—Disease—KIT—bone cancer	2.88e-06	0.000196	CbGpPWpGaD
Epirubicin—ABCC1—Disease—BRAF—bone cancer	2.7e-06	0.000184	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—KIT—bone cancer	2.52e-06	0.000172	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—BRAF—bone cancer	2.37e-06	0.000161	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—PTGS2—bone cancer	2.33e-06	0.000159	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—EGFR—bone cancer	2.3e-06	0.000156	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—PTGS2—bone cancer	2.29e-06	0.000156	CbGpPWpGaD
Epirubicin—ABCC1—Disease—MDM2—bone cancer	2.27e-06	0.000154	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PTGS2—bone cancer	2.18e-06	0.000149	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MDM2—bone cancer	1.99e-06	0.000135	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—PTGS2—bone cancer	1.83e-06	0.000124	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—JUN—bone cancer	1.73e-06	0.000117	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MMP9—bone cancer	1.68e-06	0.000114	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EGFR—bone cancer	1.55e-06	0.000105	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EGFR—bone cancer	1.36e-06	9.24e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TP53—bone cancer	1.14e-06	7.75e-05	CbGpPWpGaD
